Frontiers in Clinical Drug Research Anti-Cancer Agents/ Atta-ur-Rahman, FRS
Material type:
TextSeries: ; Vol. 2Publication details: UAE:; Bentham Science Publisher,; 2015.Description: 377 pagesISBN: - 978-1-68108-073-4
| Item type | Current library | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|
Book
|
Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD) Library | RM301.27.F76_2015 (Browse shelf(Opens below)) | Available | P 2982 |
Browsing Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD) Library shelves Close shelf browser (Hides shelf browser)
| No cover image available | No cover image available | No cover image available |
|
No cover image available | No cover image available |
|
||
| RM301.27.A88_2020 Frontiers in Clinical Drug Research: Hematology/ | RM301.27.A88_2020 Frontiers in Clinical Drug Research CNS and Neurological Disorders | RM301.27.A88_2020 Frontiers in Clinical Drug Research CNS and Neurological Disorders/ | RM301.27.F76_2015 Frontiers in Clinical Drug Research Anti-Cancer Agents/ | RM301.27.F76_2019 Frontiers in Clinical Drug Research Anti-Cancer Agents/ | RM301.27.F76_2021 Frontiers in Clinical Drug Research Anti-Cancer Agents/ | RM301.27.F76_2021 Frontiers in Clinical Drug Research Anti-Cancer Agents/ |
Frontiers in Clinical Drug Research - Anti-Cancer Agents - Volume 1 should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field. The chapters in this volume have been written by leading experts from the field.
The contents of this book include new approaches to cancer therapy, treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors, targeting key signaling pathways in pediatric brain tumors, current status of cladribine in lymphoid and myeloid malignancies, natural anti-cancer products and the mechanisms of telomere and telomerase regulation in hematologic malignancies.
The eBook series is essential to all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the field. The readers will find these reviews valuable and will certainly trigger further research in the pharmaceutical development of anti-cancer agents.